Vortosiran in Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.
Also called NCT07870889
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT07870889 -
2026-525417-31
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark, Norway, Poland, Sweden
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07870889. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-01 (anticipated); primary completion 2028-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vortosiran in Atrial Fibrillation
- Condition
- Non-valvular Atrial Fibrillation (AF)
- Intervention (Drug)
- Vortosiran
- Intervention (Drug)
- Vortosiran
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Ribocure Pharmaceuticals AB
- Collaborator
- Link Medical Research AB
Record details
- Record id
cardio:ct-nct07870889- Content hash
87f79ede2a2b715ecd5050dee6fa4bf0f7d7bb2db77755b76e072d21b853cad2